The Myelodysplastic Syndromes Channel on VJHemOnc is an independent medical education platform, supported with funding from Geron (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2024 | Biomarker analysis of luspatercept versus epoetin alfa in LR-MDS in the Phase III COMMANDS study
Uwe Platzbecker, MD, University of Leipzig, Leipzig, Germany, discusses a biomarker analysis from the Phase III COMMANDS study (NCT03682536) comparing luspatercept and epoetin alfa in patients with lower-risk myelodysplastic syndromes (LR-MDS). Luspatercept showed higher response rates in ring sideroblast (RS)-positive patients, and response rates were comparable between the two arms in RS-negative patients. Additionally, luspatercept improved biomarkers related to inflammatory pathways and heart function. This interview took place at the 29th Congress of the European Hematology Association (EHA) in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Consultancy: AbbVie, Novartis, Jazz, Bristol Myers Squibb, Servier, Janssen Biotech, Syros, Amgen, Curis, Geron, Silence Therapeutics, Takeda
Honoraria: Novartis, Jazz, Bristol Myers Squibb, Servier, Syros, Celgene, Silence Therapeutics, Takeda
Research Funding: Novartis, Roche, BeiGene, Jazz, Bristol Myers Squibb, Servier, Janssen Biotech, Syros, Merck, Fibrogen, Amgen, Curis, Geron, BMS, Silence Therapeutics, Takeda
Board of Directors/Advisory Committee: MDS Foundation, Bristol Myers Squibb
Travel Support: Bristol Myers Squibb
Medical Writing Support: Bristol Myers Squibb
